Scholarlink

<p>Europe has played a foundational role in understanding hypertrophic cardiomyopathy (HCM), yet surgical treatment—particularly septal myectomy—has seen uneven adoption across the continent. Widespread reliance on alcohol septal ablation (ASA) and the more recent introduction of cardiac myosin inhibitors (CMIs) have contributed to a decline in surgical expertise. This perspective reviews the historical evolution of HCM surgery in Europe and the impact of contemporary figures and centers. Drawing on direct correspondence with active European surgeons and institutional data, the manuscript outlines the status of myectomy programs, revealing wide disparities in access, volume, and national coordination. With the data attained here, only three European centers perform more than 25 septal myectomies per year. It also evaluates the clinical and economic implications of surgical versus pharmacological approaches. Emphasis is placed on the urgent need for structured training, procedural standardization, and broader recognition of myectomy as a definitive and cost-effective treatment for obstructive HCM.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Surgery for hypertrophic obstructive cardiomyopathy: the European perspective

  • 期刊论文

  • 发表日期：

    2026年1月15日

查看全文
  • Eduard Quintana,
  • Polina Danchenko,
  • Kostiantyn Rudenko,
  • Sertaç Cicek,
  • Alex Shipolini,
  • Jerry Braun,
  • Christophe Baufreton,
  • Patrick O. Myers,
  • Gloria Färber,
  • Julia Dumfarth,
  • Sara Ranchordás,
  • Gvido Varpins,
  • Peteris Stradins,
  • Lucian Dorobantu,
  • Maciej Kolowca,
  • Ruggero De Paulis,
  • Kamran K. Musayev,
  • Ehud Raanani,
  • Shahab Nozohoor,
  • Daniel Pereda,
  • Carlos Alberto Mestres

摘要

Europe has played a foundational role in understanding hypertrophic cardiomyopathy (HCM), yet surgical treatment—particularly septal myectomy—has seen uneven adoption across the continent. Widespread reliance on alcohol septal ablation (ASA) and the more recent introduction of cardiac myosin inhibitors (CMIs) have contributed to a decline in surgical expertise. This perspective reviews the historical evolution of HCM surgery in Europe and the impact of contemporary figures and centers. Drawing on direct correspondence with active European surgeons and institutional data, the manuscript outlines the status of myectomy programs, revealing wide disparities in access, volume, and national coordination. With the data attained here, only three European centers perform more than 25 septal myectomies per year. It also evaluates the clinical and economic implications of surgical versus pharmacological approaches. Emphasis is placed on the urgent need for structured training, procedural standardization, and broader recognition of myectomy as a definitive and cost-effective treatment for obstructive HCM.